Form 4: Spyre Therapeutics CFO Sells Shares Under 10b5-1 Plan

Spyre Therapeutics Chief Financial Officer Scott L. Burrows exercised options and sold 12,500 shares of common stock as part of a pre-arranged trading plan.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc., executed a transaction involving the exercise of stock options and the subsequent sale of 12,500 shares on May 1, 2026.
• The options were exercised at a price of 14.50 per share.
• The shares were sold at a market price of 71.37 per share, resulting in gross proceeds of approximately 892,125.
• The transaction was conducted under a Rule 10b5-1 trading plan, which was previously adopted on November 10, 2025.
• Following these transactions, Burrows directly owns 97,994 shares of common stock.
• The remaining ownership includes 67,476 restricted stock units (RSUs) scheduled to vest in 2026 and 2027.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event because the sale was automated and the CFO retains a very large vested and unvested stake in the company's future.

Positives

• The CFO maintains a significant equity stake in the company, holding 97,994 shares and 382,357 derivative securities after the sale.
• The sale was executed under a Rule 10b5-1 plan, which provides an affirmative defense against insider trading by pre-scheduling trades.
• The stock price at the time of sale (71.37) represents a substantial 392 percent gain over the exercise price (14.50).

Negatives

• The sale reduces the CFO's direct common stock holdings by approximately 11 percent (excluding RSUs and unvested options).
• Insider selling can occasionally be interpreted by the market as a signal that management believes the stock may be reaching a short-term valuation peak.

Risks

• The CFO's remaining equity incentives are subject to continued employment, posing a retention risk if key management were to depart.
• Future stock price volatility could impact the value of the 382,357 remaining stock options held by the reporting person.

Future Outlook

The CFO remains heavily incentivized through a combination of 67,476 RSUs and 382,357 stock options that continue to vest through late 2027, aligning management interests with long-term share price appreciation.

Management Comments

• The transaction was executed pursuant to a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that in the high-growth biotechnology sector, executives frequently utilize 10b5-1 plans to manage personal liquidity and tax obligations following significant stock price runs, which appears to be the case here given the high sale price relative to the exercise price.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan is consistent with corporate governance best practices at other clinical-stage biotech firms such as BridgeBio Pharma or Rocket Pharmaceuticals.
• The CFO's retention of over 80 percent of his total potential equity position (including unvested options) is a positive sign compared to more aggressive insider liquidations.

Corporate Governance

Related Party Transactions

• The transaction involves the exercise of options and sale of stock by the Chief Financial Officer, a primary insider.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event rather than a fundamental shift in company prospects.
• The CFO's continued high level of equity ownership maintains alignment with shareholder interests.

Next Steps

• Vesting of the next tranche of RSUs on September 1, 2026.
• Continued monthly vesting of the remaining 382,357 stock options.

Key Dates

Recommendation

The insider activity is routine and pre-planned, suggesting no immediate change in the company's internal outlook. Investors should focus on upcoming clinical milestones rather than this specific liquidity event.

Keywords

Spyre Therapeutics, SYRE, Insider Trading, CFO, Stock Options, Rule 10b5-1, Biotechnology, Form 4